Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
PMX is a Korean medical AI company whose core narrative is "transforming brain healthcare with AI." Its product line covers deep learning-based brain MRI AI analysis, Phenotype AI, the medical heterogeneous data platform MediOMx, and inCare for mental health care. It is not positioned to replace doctors, but rather emphasizes augmenting the judgment capabilities of medical professionals, helping to improve diagnostic efficiency and decision-making quality.
Based on the scraped content, PMX focuses on brain MRI and medical imaging AI: including the MRI AI Agent for detailed brain health analysis, MediOMx for integrating medical imaging/data, and inCare for 24/7 mental health care. The official website also mentions a technical collaboration with Samsung Seoul Hospital on brain MRI applications for sleep behavior disorders, as well as a direction for comprehensive digital medical solutions for degenerative brain MRI. Its capabilities lean more towards vertical medical scenarios rather than general-purpose AI tools.
The main text of the official website does not disclose pricing, procurement models, free quotas, or public trial information; it only mentions that MinOMx/inCare had Beta App development and Beta releases. Integration methods with hospital systems such as API, SDK, and PACS/HIS/RIS are also not explicitly stated. For medical institutions, subsequent business communication is required to confirm deployment formats, localization support, service levels, and acceptance criteria.
The advantage lies in its focused direction, forming a product matrix around brain MRI, medical imaging, and mental health; the official website discloses US FDA approval, medical device software GMP, patent applications, and multiple partner details, indicating a certain foundation in medical compliance and industry collaboration. The shortcomings are also obvious: it lacks model performance metrics, clinical validation samples, boundaries of applicable diseases, privacy compliance details, and pricing information, making it difficult to judge actual efficacy and procurement costs based solely on the website.
PMX is more suitable for collaborative evaluation by hospitals, imaging centers, neurology/radiology teams, and medical AI partners. General consumers interested in inCare will also need to wait for a clearer B2C release and service description. Access from China is not provided on the official website and is therefore deemed unknown; meanwhile, no Chinese language support or Chinese payment options were seen. For domestic (Chinese) alternatives, one can look at medical imaging AI vendors such as Shukun Technology, Infervision, Deepwise Healthcare, and United Imaging Intelligence.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on phenomx.co.kr official site.
phenomx.co.kr is an South Korea AI Apps provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach phenomx.co.kr directly.